SHIP1 is targeted by miR-155 in acute myeloid leukemia

Xue,Hua; Hua,Luo-Ming; Guo,Ming; Luo,Jian-Min

doi:10.3892/or.2014.3435

SHIP1 is targeted by miR-155 in acute myeloid leukemia

Authors:
- Hua Xue
- Luo-Ming Hua
- Ming Guo
- Jian-Min Luo
View Affiliations

Affiliations: Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Department of Hematology, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China
Published online on: August 22, 2014 https://doi.org/10.3892/or.2014.3435
Pages: 2253-2259

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The SH2 domain-containing inositol 5'-phosphatase 1 (SHIP1) has been implicated as a suppressor of hematopoietic transformation as its activity can inhibit the PI3K/Akt signaling pathway. Reduced activity of SHIP1 has been observed in acute myeloid leukemia (AML). SHIP1 is a target of microRNA-155 (miR-155). Therefore, the aim of the present study was to investigate the role of miR-155/SHIP1 in the pathogenesis of AML. We examined the levels of SHIP1 protein and miR-155 in tissue samples of patients with AML and in AML cell lines. In addition, we investigated cell proliferation, apoptosis and expression of SHIP1/PI3K/AKT pathway molecules in the THP-1 and U937 cell lines after miR-155 inhibitor or mimics were transfected. We showed that the levels of SHIP1 protein were significantly decreased in tissue samples of patients with some subtypes of AML (M4 or M5) and in AML cell lines with concomitant overexpression of miR-155. In addition, we demonstrated that decreased expression of SHIP1 in the AML cell lines was a consequence of increased levels of miR-155 and can therefore be reversed in vitro through inhibition of miR-155, with subsequent inhibition of cell proliferation and promotion of cell apoptosis. In conclusion, expression of the SHIP1 protein is targeted by miR-155 in AML. miR-155 acts as an onco-miR, and the miR-155/SHIP1/PI3K/AKT signaling pathway could play an important role in the pathogenesis of AML.

View Figures

View References

1	Hamilton MJ, Ho VW, Kuroda E, et al: Role of SHIP in cancer. Exp Hematol. 39:2–13. 2011. View Article : Google Scholar
2	Conde C, Gloire G and Piette J: Enzymatic and non-enzymatic activities of SHIP-1 in signal transduction and cancer. Biochem Pharmacol. 82:1320–1334. 2011. View Article : Google Scholar : PubMed/NCBI
3	Costinean S, Sandhu SK, Pedersen IM, et al: Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood. 114:1374–1382. 2009. View Article : Google Scholar : PubMed/NCBI
4	Kennah M, Yau TY, Nodwell M, et al: Activation of SHIP via a small molecule agonist kills multiple myeloma cells. Exp Hematol. 37:1274–1283. 2009. View Article : Google Scholar
5	Lo TC, Barnhill LM, Kim Y, Nakae EA, Yu AL and Diccianni MB: Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk Res. 33:1562–1566. 2009. View Article : Google Scholar : PubMed/NCBI
6	Luo JM, Yoshida H, Komura S, et al: Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia. Leukemia. 17:1–8. 2003. View Article : Google Scholar : PubMed/NCBI
7	Gilby DC, Goodeve AC, Winship PR, Valk PJ, Delwel R and Reilly JT: Gene structure, expression profiling and mutation analysis of the tumour suppressor SHIP1 in Caucasian acute myeloid leukaemia. Leukemia. 21:2390–2393. 2007. View Article : Google Scholar : PubMed/NCBI
8	O’Connell RM, Zhao JL and Rao DS: MicroRNA function in myeloid biology. Blood. 118:2960–2969. 2011.
9	Teng G and Papavasiliou FN: Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci. 364:631–637. 2009. View Article : Google Scholar : PubMed/NCBI
10	Tili E, Croce CM and Michaille JJ: miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol. 28:264–284. 2009. View Article : Google Scholar : PubMed/NCBI
11	O’Connell RM, Chaudhuri AA, Rao DS and Baltimore D: Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 106:7113–7118. 2009.PubMed/NCBI
12	Schwind S, Maharry K, Radmacher MD, et al: Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 28:5257–5264. 2010. View Article : Google Scholar : PubMed/NCBI
13	Pedersen IM, Otero D, Kao E, et al: Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med. 1:288–295. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yamanaka Y, Tagawa H, Takahashi N, et al: Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 114:3265–3275. 2009. View Article : Google Scholar
15	Metzner A, Precht C, Fehse B, et al: Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D. Gene Ther. 16:570–573. 2009. View Article : Google Scholar : PubMed/NCBI
16	O’Connell RM, Rao DS, Chaudhuri AA, et al: Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 205:585–594. 2008.PubMed/NCBI
17	Sayed D and Abdellatif M: AKT-ing via microRNA. Cell Cycle. 9:3213–3217. 2010. View Article : Google Scholar : PubMed/NCBI
18	Volinia S, Galasso M, Costinean S, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20:589–599. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhi F, Cao X, Xie X, et al: Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. PLoS One. 8:e567182013. View Article : Google Scholar : PubMed/NCBI
20	Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E and Dervenoulas J: The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol. 84:1–16. 2010. View Article : Google Scholar : PubMed/NCBI
21	Faraoni I, Antonetti FR, Cardone J and Bonmassar E: miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 1792:497–505. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wang Y, Li Z, He C, et al: MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis. 44:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yuan Y, Kasar S, Underbayev C, Prakash S and Raveche E: MicroRNAs in acute myeloid leukemia and other blood disorders. Leuk Res Treatment. 2012:6038302012.PubMed/NCBI
24	Lawrie CH: MicroRNAs and haematology: small molecules, big function. Br J Haematol. 137:503–512. 2007. View Article : Google Scholar : PubMed/NCBI
25	Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-McIver A and Young BD: MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia. 21:912–916. 2007.PubMed/NCBI
26	Hyde RK and Liu PP: The role of microRNAs in acute myeloid leukemia. F1000 Biol Rep. 2:812010.PubMed/NCBI
27	Joyce CE and Novina CD: miR-155 in acute myeloid leukemia: not merely a prognostic marker? J Clin Oncol. 31:2219–2221. 2013. View Article : Google Scholar : PubMed/NCBI
28	Baran CP, Tridandapani S, Helgason CD, Humphries RK, Krystal G and Marsh CB: The inositol 5′-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity. J Biol Chem. 278:38628–38636. 2003.
29	Blunt MD and Ward SG: Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Curr Opin Pharmacol. 12:444–451. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ong CJ, Ming-Lum A, Nodwell M, et al: Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood. 110:1942–1949. 2007. View Article : Google Scholar : PubMed/NCBI